Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762
文献类型：期刊论文
| 作者 | Wang, Jing-Nan1,2; Che, Yun1,2; Yuan, Zu-Yang1,2; Lu, Zhi-Liang1,2; Li, Yuan1,2; Zhang, Zhi-Rong1,2 ; Li, Ning1,2; Li, Ren-Da1,2; Wan, Jun3; Sun, Han-Dong3
|
| 刊名 | TOXICOLOGY AND APPLIED PHARMACOLOGY
 |
| 出版日期 | 2019-02-15 |
| 卷号 | 365页码:71-83 |
| 关键词 | Acetyl-macrocalin B Reactive oxygen species p38 MAPK Chk1/Chk2 Esophageal squamous cell carcinoma |
| ISSN号 | 0041-008X |
| 英文摘要 | Natural products derived from herbal medicines have become a major focus of anti-cancer drug discovery studies. Acetyl-macrocalin B (A-macB) is an ent-diterpenoid isolated from Isodon silvatica. This study aimed to examine the effect and molecular action of A-macB in esophageal squamous cell carcinoma (ESCC) and explore possible drug synergistic modalities. A-macB induced cellular reactive oxygen species (ROS) generation, initiated the p38 mitogen-activated protein kinase (MAPK) signaling pathway, and triggered the caspase-9-dependent apoptosis cascade in ESCC cells. The ROS scavenger N-acetylcysteine (NAC) and the specific p38 inhibitor 5B203580 reversed the effects of A-macB on the p38 network and thus rescued ESCC cells from apoptosis. The cellular ROS increase was at least partially due to the suppression of glutathione-S-transferase P1 (GSTP1) by A-macB. A-macB also upregulated the Chk1/Chk2-Cdc25C/Cdc2/Cyclin B1 axis to induce G2/M phase arrest. The cell growth inhibition induced by A-macB was further enhanced by AZD7762, a specific Chk1/Chk2 inhibitor, with a combination index (CI) of < 1. Moreover, A-macB efficiently suppressed xenograft growth without inducing significant toxicity, and AZD7762 potentiated the effects of A-macB in the suppression of tumor growth in vivo. Taken together, A-macB is a promising lead compound for ESCC and exerts synergistic anti-cancer effects with AZD7762. |
| 资助项目 | CAMS Innovation Fund for Medical Sciences (CIFMS)[2016-I2M-1-001] ; National Key Basic Research Development Plan[2015CB553901] ; National Natural Science Foundation of China[81372219] ; National Natural Science Foundation of China[81673329] ; Chinese Academy of Medical Sciences Central Public-interest Scientific Institution Basal Research Fund[2016ZX310196] ; NSFC-Joint Foundation of Yunnan Province[U1302223] |
| 语种 | 英语 |
| 资助机构 | CAMS Innovation Fund for Medical Sciences (CIFMS) ; National Key Basic Research Development Plan ; National Natural Science Foundation of China ; Chinese Academy of Medical Sciences Central Public-interest Scientific Institution Basal Research Fund ; NSFC-Joint Foundation of Yunnan Province |
| 源URL | [http://ir.kib.ac.cn/handle/151853/64177]  |
| 专题 | 昆明植物研究所_植物化学与西部植物资源持续利用国家重点实验室 |
| 通讯作者 | Sun, Nan; Puno, Pema-Tenzin; He, Jie |
| 作者单位 | 1.Chinese Acad Med Sci, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Thorac Surg, 17 Panjiayuan Nan Li, Beijing 100021, Peoples R China 2.Peking Union Med Coll, 17 Panjiayuan Nan Li, Beijing 100021, Peoples R China 3.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Jing-Nan,Che, Yun,Yuan, Zu-Yang,et al. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY,2019,365:71-83. |
| APA | Wang, Jing-Nan.,Che, Yun.,Yuan, Zu-Yang.,Lu, Zhi-Liang.,Li, Yuan.,...&He, Jie.(2019).Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.TOXICOLOGY AND APPLIED PHARMACOLOGY,365,71-83. |
| MLA | Wang, Jing-Nan,et al."Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762".TOXICOLOGY AND APPLIED PHARMACOLOGY 365(2019):71-83. |
入库方式： OAI收割
来源：昆明植物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。